Trial Profile
A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 May 2015
Price :
$35
*
At a glance
- Drugs Flurpiridaz F 18 (Primary)
- Indications Coronary artery disease
- Focus Diagnostic use; Registrational
- Sponsors Lantheus Medical Imaging
- 04 May 2015 Based on results of the first phase III trial, Lantheus will conduct a new second phase III trial with a redesigned protocol and different primary endpoints, according to a media release.
- 19 Feb 2014 New trial record